• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

致心律失常性右室心肌病室性心律失常的新预测模型。

A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy.

机构信息

Division of Cardiology, Department of Medicine, Johns Hopkins Hospital, Carnegie 568D, 600 N. Wolfe St. Baltimore, MD, USA.

Cardiovascular Genetics Center, Montreal Heart Institute, Université de Montréal, 5000 Bélanger St, Montréal, Canada.

出版信息

Eur Heart J. 2022 Aug 21;43(32):e1-e9. doi: 10.1093/eurheartj/ehac180.

DOI:10.1093/eurheartj/ehac180
PMID:35441664
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9392651/
Abstract

AIMS

Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC) is characterized by ventricular arrhythmias (VAs) and sudden cardiac death (SCD). We aimed to develop a model for individualized prediction of incident VA/SCD in ARVC patients.

METHODS AND RESULTS

Five hundred and twenty-eight patients with a definite diagnosis and no history of sustained VAs/SCD at baseline, aged 38.2 ± 15.5 years, 44.7% male, were enrolled from five registries in North America and Europe. Over 4.83 (interquartile range 2.44-9.33) years of follow-up, 146 (27.7%) experienced sustained VA, defined as SCD, aborted SCD, sustained ventricular tachycardia, or appropriate implantable cardioverter-defibrillator (ICD) therapy. A prediction model estimating annual VA risk was developed using Cox regression with internal validation. Eight potential predictors were pre-specified: age, sex, cardiac syncope in the prior 6 months, non-sustained ventricular tachycardia, number of premature ventricular complexes in 24 h, number of leads with T-wave inversion, and right and left ventricular ejection fractions (LVEFs). All except LVEF were retained in the final model. The model accurately distinguished patients with and without events, with an optimism-corrected C-index of 0.77 [95% confidence interval (CI) 0.73-0.81] and minimal over-optimism [calibration slope of 0.93 (95% CI 0.92-0.95)]. By decision curve analysis, the clinical benefit of the model was superior to a current consensus-based ICD placement algorithm with a 20.3% reduction of ICD placements with the same proportion of protected patients (P < 0.001).

CONCLUSION

Using the largest cohort of patients with ARVC and no prior VA, a prediction model using readily available clinical parameters was devised to estimate VA risk and guide decisions regarding primary prevention ICDs (www.arvcrisk.com).

摘要

目的

致心律失常性右室心肌病(ARVC)的特征是室性心律失常(VA)和心脏性猝死(SCD)。我们旨在建立一种预测 ARVC 患者发生 VA/SCD 的个体化模型。

方法和结果

本研究纳入了来自北美和欧洲五个登记处的 528 名明确诊断且基线时无持续性 VA/SCD 病史的患者,年龄为 38.2±15.5 岁,其中 44.7%为男性。在 4.83 年(四分位距 2.44-9.33)的随访期间,146 名患者(27.7%)经历了持续性 VA,定义为 SCD、SCD 中止、持续性室性心动过速或适当的植入式心脏复律除颤器(ICD)治疗。采用 Cox 回归和内部验证建立了预测 VA 年风险的模型。预先指定了 8 个潜在预测因子:年龄、性别、过去 6 个月的心脏性晕厥、非持续性室性心动过速、24 小时内的室性期前收缩数、T 波倒置导联数和右心室和左心室射血分数(LVEF)。除 LVEF 外,其余因子均保留在最终模型中。该模型能准确区分有和无事件的患者,经校正后的 optimism-corrected C 指数为 0.77(95%CI 0.73-0.81),且最小化了过度乐观的情况[校准斜率为 0.93(95%CI 0.92-0.95)]。通过决策曲线分析,该模型的临床获益优于当前基于共识的 ICD 放置算法,在相同比例的受保护患者中,可减少 20.3%的 ICD 放置(P<0.001)。

结论

本研究使用了最大的 ARVC 患者队列,且患者无先前的 VA,开发了一种使用易于获得的临床参数预测 VA 风险的模型,以指导关于原发性预防 ICD 的决策(www.arvcrisk.com)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60cd/9392651/5a5520b56cfd/ehac180f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60cd/9392651/b64184c8c496/ehac180f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60cd/9392651/41e9cfd549ae/ehac180f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60cd/9392651/a88340ff0c22/ehac180f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60cd/9392651/21cd4e0639c8/ehac180f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60cd/9392651/5a5520b56cfd/ehac180f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60cd/9392651/b64184c8c496/ehac180f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60cd/9392651/41e9cfd549ae/ehac180f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60cd/9392651/a88340ff0c22/ehac180f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60cd/9392651/21cd4e0639c8/ehac180f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60cd/9392651/5a5520b56cfd/ehac180f5.jpg

相似文献

1
A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy.致心律失常性右室心肌病室性心律失常的新预测模型。
Eur Heart J. 2022 Aug 21;43(32):e1-e9. doi: 10.1093/eurheartj/ehac180.
2
A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy.致心律失常性右室心肌病室性心律失常的新预测模型。
Eur Heart J. 2019 Jun 14;40(23):1850-1858. doi: 10.1093/eurheartj/ehz103.
3
Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy: A Multinational Collaboration.致心律失常性右室心肌病中心律失常性猝死预测:一项多国合作研究。
Circ Arrhythm Electrophysiol. 2021 Jan;14(1):e008509. doi: 10.1161/CIRCEP.120.008509. Epub 2020 Dec 9.
4
Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator.心律失常性右室心肌病的心律失常风险预测:心律失常性右室心肌病风险计算器的外部验证。
Eur Heart J. 2022 Aug 21;43(32):3041-3052. doi: 10.1093/eurheartj/ehac289.
5
Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and Europe.在北美和欧洲,植入式心脏复律除颤器在致心律失常性右心室心肌病中的应用。
Eur Heart J. 2024 Feb 16;45(7):538-548. doi: 10.1093/eurheartj/ehad799.
6
Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia Without an Implantable Cardioverter-Defibrillator.致心律失常性右室心肌病/发育不良患者的风险分层,无需植入式心脏复律除颤器。
JACC Clin Electrophysiol. 2018 Jun;4(6):757-768. doi: 10.1016/j.jacep.2018.04.017.
7
Incidence and predictors of sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy: a pooled analysis.致心律失常性右室心肌病中心律失常性猝死的发生率及预测因素:一项汇总分析。
Europace. 2022 Oct 13;24(10):1665-1674. doi: 10.1093/europace/euac014.
8
Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy.比较心律失常性右心室心肌病中当前植入式心脏复律除颤器植入建议的临床性能。
Europace. 2022 Feb 2;24(2):296-305. doi: 10.1093/europace/euab162.
9
Long-term follow-up of arrhythmogenic right ventricular cardiomyopathy patients with an implantable cardioverter-defibrillator for prevention of sudden cardiac death.植入式心脏复律除颤器预防致心律失常性右室心肌病患者心源性猝死的长期随访
Clin Cardiol. 2017 Apr;40(4):216-221. doi: 10.1002/clc.22648. Epub 2017 Jan 31.
10
Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment.北美多学科 ARVC 研究中心的室性心律失常:预测因素、特征和治疗。
J Am Coll Cardiol. 2014 Jul 15;64(2):119-25. doi: 10.1016/j.jacc.2014.04.035.

引用本文的文献

1
Left Ventricular Ring-like Pattern: The Arrhythmic Tale of a Scarred Heart.左心室环状模式:一颗伤痕累累心脏的心律失常故事。
J Cardiovasc Dev Dis. 2025 Jul 17;12(7):275. doi: 10.3390/jcdd12070275.
2
Machine Learning Models Enhance Prediction of Arrhythmogenic Right Ventricular Cardiomyopathy.机器学习模型增强致心律失常性右室心肌病的预测
medRxiv. 2025 Jun 17:2025.06.16.25329706. doi: 10.1101/2025.06.16.25329706.
3
Family Screening in Relatives at Risk for Plakophilin-2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy.

本文引用的文献

1
Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy.2015 年国际工作组共识声明风险分层算法在致心律失常性右室心肌病/发育不良中的植入式心脏复律除颤器放置中的表现。
Circ Arrhythm Electrophysiol. 2018 Feb;11(2):e005593. doi: 10.1161/CIRCEP.117.005593. Epub 2018 Feb 16.
2
Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: A systematic review and meta-analysis.预测致心律失常性右室心肌病的心律失常风险:系统评价和荟萃分析。
Heart Rhythm. 2018 Jul;15(7):1097-1107. doi: 10.1016/j.hrthm.2018.01.031. Epub 2018 Feb 3.
3
对患与桥粒斑菲素蛋白2相关的致心律失常性右室心肌病风险的亲属进行家族筛查。
Circulation. 2025 Jun 17. doi: 10.1161/CIRCULATIONAHA.125.074058.
4
Highlights 2024.2024年亮点
Radiol Cardiothorac Imaging. 2025 Jun;7(3):e250064. doi: 10.1148/ryct.250064.
5
China Multi-Center Cohort Study on Risk Evaluation of Arrhythmogenic Cardiomyopathy: The ChinaCORE ACM Registry.中国致心律失常性心肌病风险评估多中心队列研究:中国CORE-ACM注册研究
JACC Asia. 2025 Jul;5(7):914-923. doi: 10.1016/j.jacasi.2025.04.005. Epub 2025 May 10.
6
Fenotypic expressions and clinical manifestations of arrhythmogenic cardiomyopathy.致心律失常性心肌病的表型表达和临床表现
Eur Heart J Suppl. 2025 Apr 16;27(Suppl 3):iii143-iii149. doi: 10.1093/eurheartjsupp/suaf033. eCollection 2025 Mar.
7
Imaging features of desmoplakin arrhythmogenic cardiomyopathy: A comparative cardiovascular magnetic resonance study.桥粒斑蛋白致心律失常性心肌病的影像学特征:一项心血管磁共振对比研究。
J Cardiovasc Magn Reson. 2025;27(1):101867. doi: 10.1016/j.jocmr.2025.101867. Epub 2025 Feb 26.
8
Risk stratification in arrhythmogenic cardiomyopathy: scoring or personalized medicine?致心律失常性心肌病的风险分层:评分法还是个性化医疗?
Eur Heart J Suppl. 2025 Feb 19;27(Suppl 1):i36-i39. doi: 10.1093/eurheartjsupp/suae098. eCollection 2025 Feb.
9
Natural History, Phenotype Spectrum, and Clinical Outcomes of Desmin ()-Associated Cardiomyopathy.结蛋白()相关心肌病的自然病史、表型谱及临床结局
Circ Genom Precis Med. 2025 Apr;18(2):e004878. doi: 10.1161/CIRCGEN.124.004878. Epub 2025 Feb 19.
10
Arrhythmic Risk Stratification of Carriers of Filamin C Truncating Variants.丝状肌动蛋白C截短变异携带者的心律失常风险分层
JAMA Cardiol. 2025 Apr 1;10(4):359-369. doi: 10.1001/jamacardio.2024.5543.
Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests.
用于评估预测模型、分子标志物和诊断测试的净效益方法。
BMJ. 2016 Jan 25;352:i6. doi: 10.1136/bmj.i6.
4
Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: A systematic review and meta-analysis of inappropriate shocks and complications.可植入式心律转复除颤器对遗传性心律失常综合征年轻患者的危害:不适当电击和并发症的系统评价和荟萃分析。
Heart Rhythm. 2016 Feb;13(2):443-54. doi: 10.1016/j.hrthm.2015.09.010. Epub 2015 Sep 15.
5
Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement.致心律失常性右室心肌病/发育异常的治疗:一项国际特别工作组共识声明
Eur Heart J. 2015 Dec 7;36(46):3227-37. doi: 10.1093/eurheartj/ehv162. Epub 2015 Jul 27.
6
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.序列变异解读的标准与指南:美国医学遗传学与基因组学学会和分子病理学协会的联合共识推荐
Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.
7
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration.透明报告个体预后或诊断的多变量预测模型(TRIPOD):解释和说明。
Ann Intern Med. 2015 Jan 6;162(1):W1-73. doi: 10.7326/M14-0698.
8
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).2014年欧洲心脏病学会(ESC)肥厚型心肌病诊断和治疗指南:欧洲心脏病学会(ESC)肥厚型心肌病诊断和治疗工作组
Eur Heart J. 2014 Oct 14;35(39):2733-79. doi: 10.1093/eurheartj/ehu284. Epub 2014 Aug 29.
9
A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).肥厚型心肌病患者心脏性猝死的新型临床风险预测模型(HCM risk-SCD)。
Eur Heart J. 2014 Aug 7;35(30):2010-20. doi: 10.1093/eurheartj/eht439. Epub 2013 Oct 14.
10
Predictors of appropriate ICD therapy in patients with arrhythmogenic right ventricular cardiomyopathy: long term experience of a tertiary care center.致心律失常性右室心肌病患者中合适的 ICD 治疗的预测因素:一家三级护理中心的长期经验。
PLoS One. 2012;7(9):e39584. doi: 10.1371/journal.pone.0039584. Epub 2012 Sep 27.